FLASH NEWS LIVE

Maze Therapeutics posts trial data for lead drug (MAZE:NASDAQ)

Maze Therapeutics posts trial data for lead drug (MAZE:NASDAQ)

Maze Therapeutics (MAZE) stock plunged even as the company posts positive Phase 2 trial data for lead asset MZE829 in APOL1-mediated kidney disease. Read more here.

Read Full Article →

📱 Tip: Tap the 🔗 Share icon in Safari and choose Add to Home Screen to install World Trade Factory.
Instagram Meta X LinkedIn Whatsapp